Patents by Inventor Stephan Brock

Stephan Brock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140296318
    Abstract: Methods of determining whether a patient is suitable for erythropoietin (EPO) therapy, including (A) isolating a tissue sample from said patient; (B) determining the level of expression of EPH-B4 in said sample; and (C) correlating a presence of EPH-B4 expression to a negative physiological response to EPO therapy). In addition, methods of enhancing the effectiveness of EPO therapy in a patient by administering to said patient, in conjunction with EPO therapy, an siRNA specific for EPH-B4.
    Type: Application
    Filed: October 22, 2013
    Publication date: October 2, 2014
    Applicant: MOLECULAR HEALTH GMBH
    Inventors: DAVID B. JACKSON, MARTIN STEIN, HARTMUT VOSS, STEPHAN BROCK, CHRISTOPHER G. DANES, ANIL SOOD
  • Publication number: 20140243134
    Abstract: A belt comprises at least a belt body made of a polymer material having elastic properties, the belt including a cover layer as a belt backing, a substructure having a force-transmission zone, and a tension member in a ribbed design embedded in the belt body. The tension member is prepared with a cross-linked polyurethane in such a way that the polyurethane fills at least part of the tension member cavities. The polyurethane filling material enters into a mechanical connection to the tension member on the one hand and an adhesive connection to the belt body on the other hand. The polyurethane filling material has a Shore A hardness that is 0.5 to 10 times harder than the Shore A hardness of the belt body. The belt body is preferably likewise made of cross-linked polyurethane, in particular using a carbon tension member.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 28, 2014
    Applicant: ContiTech Antriebssysteme GmbH
    Inventors: Andre Kucharczyk, Hubert Goeser, Markus Obert, Stephan Brocke
  • Publication number: 20140238581
    Abstract: A method for treating a tension member in the production of a belt. The belt includes at least a belt body made of a polymer material having elastic properties, a cover layer as a belt backing, and a substructure having a force-transmission zone. The tension member has a ribbed design and is embedded in the belt body. The tension member is treated with an overall treatment mixture which forms a cross-linked polymer that on the one hand enters into a mechanical connection with the tension member and on the other hand forms an adhesive connection with the belt body.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 28, 2014
    Applicant: ContiTech Antriebssysteme GmbH
    Inventors: Stephan Brocke, Hubert Goeser, Andre Kucharczyk
  • Publication number: 20130268290
    Abstract: Systems and methods are described herein for disease knowledge modeling and clinical treatment decision support, and the prioritization of possible treatment options based on tumor or other disease biomarkers. Disease or indication information, including identification of biomolecular entities associated with the indication may be culled through text data mining to create a knowledge model of the indication. In some embodiments, the knowledge model may comprise a network of associations between molecular entities, including such drug targets and biomakers, genes, pathways. The model may be combined with patient-specific variant information and historical treatment records to identify and prioritize treatment decisions and allow for the prediction of disease drivers and provide treatment options tailored to a patient's genetic data.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 10, 2013
    Inventors: DAVID JACKSON, Stephan Brock, Alexander Zien
  • Publication number: 20130179091
    Abstract: The present disclosure is directed to systems and methods for identifying unknown drug targets via adverse event data. An analyzer receives an identification of a first drug having one or more unknown target proteins and identifies a second drug related to the first drug. The analyzer retrieves, from an adverse event database, a first side effect profile associated with the first drug, and a second side effect profile associated with the second drug. The analyzer generates a third side effect profile comprising a subset of the first side effect profile not shared by the second side effect profile, and identifies a third drug having a fourth side effect profile comprising the third side effect profile. The analyzer retrieves a list of one or more target proteins of the third drug not targeted by the second drug, and presents the retrieved list as potential target proteins of the first drug.
    Type: Application
    Filed: April 13, 2012
    Publication date: July 11, 2013
    Inventors: David Jackson, Theodoros Soldatos, Guillaume Taglang, Alexander Zien, Stephan Brock
  • Publication number: 20130179138
    Abstract: The present disclosure describes systems and methods for predicting a likely side effect profile for even new, untested medications. A predicted side effect profile may be generated based on intersections of side effect profiles of other medications that affect the same or related molecular entities, such as the nearby target proteins, involve the same pathways, or are otherwise similarly related. To generate a predicted side effect profile for a new drug targeting a novel or previously un-targeted protein target, an analyzer may query an adverse event database for records pertaining to patients who have taken drugs or combinations of drugs that target or affect molecular entities in the vicinity of the novel target within a global molecular entity graph, and, in some embodiments, may retrieve a plurality of adverse event records and generate an intersection of side effects associated with related targets to predict likely side effects for the novel target.
    Type: Application
    Filed: April 13, 2012
    Publication date: July 11, 2013
    Inventors: David Jackson, Theodoros Soldatos, Guillaume Taglang, Alexander Zien, Stephan Brock
  • Publication number: 20130179187
    Abstract: The present disclosure describes systems and methods for de-risking patient treatment by identifying medications or combinations of medications to be contraindicated for a specific indication. An analyzer executed by a processor of a computing device from a user may receive an identification of an indication (e.g. the subject of a clinical trial, or the diagnosis of a patient visiting a physician's office). The analyzer may retrieve, from an adverse event database, medication and co-medication information of patients that experienced a side effect corresponding to the indication. The analyzer may sort the retrieved medication and co-medication information to generate an ordered list of medications consumed by patients that experienced the side effect, and identify a first medication of the ordered list. A display module executed by the computing device may display, to the user, the first medication of the ordered list for contraindication from the clinical trial.
    Type: Application
    Filed: April 13, 2012
    Publication date: July 11, 2013
    Inventors: David Jackson, Theodoros Soldatos, Guillaume Taglang, Alexander Zien, Stephan Brock
  • Publication number: 20130179181
    Abstract: The present disclosure describes systems and methods for using patient-specific genomic information to optimize or de-risk therapy for the patient. A user may identify a medication for consideration for prescription to a patient, and a genetic variant of the patient affecting a first protein. An analyzer may identify a second medication targeting the first protein, and may retrieve adverse event data from an adverse event database for patients co-medicated with both the first medication and second medication. The analyzer may determine, based on rates of adverse events, the likelihood of an adverse event occurring through co-medication of the first medication and second medication. Based on the likelihood, and based on a correspondence or non-correspondence between a protein activation characteristic of the first medication and the effect of the genetic variant of the patient, the analyzer may indicate or contra-indicate the first medication for the patient.
    Type: Application
    Filed: April 13, 2012
    Publication date: July 11, 2013
    Inventors: David Jackson, Theodoros Soldatos, Guillaume Taglang, Alexander Zien, Stephan Brock
  • Patent number: 8357501
    Abstract: There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumor allows EPO to impinge on the survival of associated cells thereby enhancing tumor progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumor as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: January 22, 2013
    Assignee: Molecular Health GmbH
    Inventors: David B. Jackson, Martin Stein, Hartmut Voss, Stephan Brock
  • Publication number: 20120329591
    Abstract: A belt for driving systems, including a belt body made of a polymeric material having elastic properties, which comprises a cover layer as a back of the belt and a foundation having a force-transmission zone, and, a tensile reinforcement embedded in the belt body. The belt body is made of at least two different materials A and B, namely: a first material A, which is provided with a fire-inhibiting additive and is used in the belt body everywhere the high mechanical properties are not required; and, a second material B, which contains little or none of a fire-inhibiting additive and is used in the area of the belt body that is subjected to great mechanical stress. The belt is used in particular as a tensile element for elevator systems.
    Type: Application
    Filed: September 6, 2012
    Publication date: December 27, 2012
    Inventors: Hubert Goeser, Thomas Winkler, Hugh J. O'Donnell, Stephan Brocke
  • Publication number: 20120245087
    Abstract: There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumour as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin.
    Type: Application
    Filed: March 8, 2011
    Publication date: September 27, 2012
    Inventors: David B. Jackson, Martin Stein, Hartmut Voss, Stephan Brock, Christopher G. Danes, Anil Sood
  • Publication number: 20090306186
    Abstract: There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumour as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin.
    Type: Application
    Filed: May 28, 2009
    Publication date: December 10, 2009
    Inventors: David B. JACKSON, Martin Stein, Hartmut Voss, Stephan Brock, Christopher G. Danes, Anil Sood